Infection of the HTLV-I-harbouring T-lymphoblastoid line MT-2 by Epstein-Barr virus

Koizumi, Shigeki; Zhang, Xian-kui; Imai, Shosuke; Sugiura, Makoto; Usui, Norio; Õsato, Toyoro

doi:10.1016/0042-6822(92)90542-w

Cited by 22 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plates were then incubated with 100 l of anti-HABP (1/4,000 dilution) or anti-EBV (1/500 dilution) sera for 2 h at 18°C. Color development was performed as mentioned above (26).…”

Section: Methodsmentioning

confidence: 99%

Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells

Urquiza

López

Patino

et al. 2005

Journal of Biological Chemistry

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) invasion of B-lymphocytes involves Epstein-Barr virus (EBV)2 invades B-lymphocytes through molecular interactions involving the EBV gp350/220 protein. It is known that gp350 binds to B-lymphocyte CR2 (known as C3d receptor) with a 3.2 nM affinity constant (12 nM affinity has been determined for B-lymphocyte surface) (1, 2). This simple 1:1 interaction is involved in adsorption, capping, and EBV endocytosis and is considered to be a primary determinant of EBV tissue tropism (3-5). The CR2 region binding to gp350 overlaps the CR2 region binding to C3dg. The gp350 N-terminal region contains part of the B-lymphocyte binding domain (5).The gp350 21 EDPGFFNVE 29 peptide, having significant homology with C3d-amino acid sequences (6), binds to purified CR2 and to CR2(ϩ) but not to CR2(Ϫ) B-and T-lymphoblastoid cell lines; this peptide coupled to BSA inhibits CR2 binding to EBV and gp350 (7). This peptide inhibits C3dg binding to B-cells (as well as EBV) and also inhibits C3-induced Raji cell proliferative response (7,8).However, the 470-mer N-terminal recombinant protein and gp220, containing this peptide sequence, present single-component binding, whereas gp350/220 presents a higher affinity two-component binding to CR2 (5, 9) and inhibits only 50% of EBV binding and EBV infection of Raji cells (5) (5). On the other hand, the C3dg region (homologous to this gp350 peptide) is not in contact with CR2 in the reported complex structure (10). It is thus very likely that other gp350/220 regions are involved in EBV binding to B-lymphocytes.The gp350/220 region containing the epitope recognized by neutralizing monoclonal antibody 72A1 is one of the most important regions involved in gp350/220 binding to B-lymphocyte CR2, because the mAb 72A1 Fab fragment inhibits EBV binding and invasion of host cells (5, 11). Moreover, mAb 72A1 inhibits EBV invasion of monocytes (12), neutrophils (13), and T-cells (14). Anti-gp350/220 mAb 72A1 also inhibits interleukin-6 (IL-6) protein synthesis induced in PBLs by gp350/220 binding to CR2 (15); it also inhibits EBV invasion of B-lymphocytes (5). It is known that the gp350/220 region involved in EBV invasion of host cells is recognized by this monoclonal antibody; however, its precise localization remains unknown. The purpose of this work was thus to identify B-lymphocyte binding sequences that are involved in EBV virus infection of B-lymphocytes. MATERIALS AND METHODSPeptide Synthesis-Forty-six peptides, covering the total length of EBV gp350-reported sequence (16), were synthesized by the solid phase method (17) with N-terminal t-Boc-protected amino acids. Peptides were cleaved by a low-high hydrogen fluoride protocol (18). These peptides were analyzed by mass spectrometry and reverse-phase high performance liquid chromatography. Synthesized peptide sequences are shown in Fig. 1. Tyrosine (Y) was C-terminally added, allowing those peptides not containing this amino acid to be radiolabeled.Lymphoblastoid Cell Line Cultures-The cloned Raji (19), Ramos (20), and P3HR-1 ...

show abstract

“…Plates were then incubated with 100 l of anti-HABP (1/4,000 dilution) or anti-EBV (1/500 dilution) sera for 2 h at 18°C. Color development was performed as mentioned above (26).…”

Section: Methodsmentioning

confidence: 99%

Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells

Urquiza

López

Patino

et al. 2005

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…The mechanisms of EBV infection to human T cells remain to be elucidated. Some T-cell lines have CD21, the receptor of EBV [38]. However, in vitro experiments have failed to demonstrate continuous presence of EBV in such T-cell lines.…”

Section: T-cell Lymphomamentioning

confidence: 95%

FROM BURKITT'S LYMPHOMA TO CHRONIC ACTIVE EPSTEIN-BARR VIRUS (EBV) INFECTION: An Expanding Spectrum of EBV-Associated Diseases

Okano¹,

Gross²

2001

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Epstein-Barr virus (FBV) is one of 8 known human herpesviruses. EBV infection usually occurs in early childhood and is subclinical. However, primary infection in adolescence or adulthood causes infectious mononucleosis in approximately half of infected individuals. Recently, the spectrum of human diseases associated with EBV injection has increased, primarily due to methodological advances in EBV detection. Initially, EBV was isolated from a cultured Burkitt lymphoma cell line, and has been felt to be etiologically linked to the development of Burkitt lymphoma, as well as other human malignancies. This review mainly focuses on pathogenetic mechanisms, many of which remain enigmatic, for the various human diseases, which are considered to be associated with EBV injection.

show abstract

“…If a larger number of cases were investigated, some peripheral stage of neoplastic T cells may be found to express the CD21 antigen, and it may be a more conceivable ready-made target neoplasm that can be infected by EBV. While all fresh ATL cells lacked the CD21 antigen in our study, Koizumi et al [24] reported that the HTLV-I-positive cell line MT2, which is of nonneoplastic origin, had the CD21 antigen and was infected by EBV.…”

Section: Discussionmentioning

confidence: 79%

CD21 antigen in T‐lineage neoplastic lymphoid cells: Characteristic expression at thymic stage

1994

View full text Add to dashboard Cite

The expression of CD21 antigen, a receptor for the C3d fragment of complement and Epstein-Barr virus (EBV), was investigated in a total of 85 cases of neoplastic lymphoid cells including 39 cases of T-lineage acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL), although CD21 antigen is usually regarded as a pan-B antigen. The CD21 antigen was expressed by one of the eight cases of neoplastic lymphoid cells expressing the CD7 antigen as a sole pan-T antigen, by three of the 20 cases of pro- or early thymic stage (CD7+ CD5+ CD2-, CD7+ CD5- CD2+, or CD7+ CD5+ CD2+, and ten of 11 cases of thymic stage (CD3+/- CD4+ CD8+), but not by one case of late thymic stage (CD3+ CD4+ CD8-) T-ALL/LBL cells. The CD21 antigen was not expressed by any of the 11 cases of adult T-cell leukemia (ATL) or two cases of chronic T-lineage leukemia. At most 4% of the normal thymocytes obtained from seven infants or children expressed the CD21 antigen. While only a very limited population of normal thymocytes expresses CD21 antigen, T-ALL/LBL cells at the thymic stage characteristically express CD21 antigen in contrast to pro- or early thymic ALL/LBL or peripheral-stage neoplastic T cells. The estimation of the expression of CD21 antigen is useful for delineating stages of differentiation in T-ALL/LBL. Furthermore, these observation are notable, considering the possibility that the reported EBV-carrying T-cell lymphomas result from the penetration of EBV into EBV-negative neoplastic T cells.

show abstract

Infection of the HTLV-I-harbouring T-lymphoblastoid line MT-2 by Epstein-Barr virus

Cited by 22 publications

References 17 publications

Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells

Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells

FROM BURKITT'S LYMPHOMA TO CHRONIC ACTIVE EPSTEIN-BARR VIRUS (EBV) INFECTION: An Expanding Spectrum of EBV-Associated Diseases

CD21 antigen in T‐lineage neoplastic lymphoid cells: Characteristic expression at thymic stage

Contact Info

Product

Resources

About